患有原发性胆道胆炎的患者的风险分层:早期与晚期或非肝硬化与肝硬化?
Dawei Ding1, Gui Jia1, Guanya Guo2
1State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, The Air Force Military Medical University, Xi'an, 710032, Shaanxi, China.
Hepatology international
|March 29, 2025
概括
初级胆道胆道炎 (PBC) 的组织学分期为非肝硬化与肝硬化比早期/高级分期更有效. 鹿特丹标准准确地评估了肝硬化PBC患者的治疗反应.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 临床医学 临床医学
背景情况:
- 初级胆道胆炎 (PBC) 进入早期和高级阶段需要验证.
- 优化PBC疾病状态的划分仍未确定.
研究的目的:
- 根据组织学阶段重新建立一次性胆道胆炎 (PBC) 的风险分层策略.
- 根据组织学和生化标志物来定义PBC的反应标准.
主要方法:
- 721名患者的回顾性分析,包括组织学数据.
- 评估与肝脏相关的死亡和肝脏移植 (LT) 作为终点事件.
- 不同风险分层模型和响应标准的比较 (巴黎I,巴黎II,鹿特丹,多伦多).
主要成果:
- 相比于III期 (p=0.002),组织学IV期与减少的无LT存活率显著相关 (p=0.002).
- 总胆红素水平与无LT存活率相关 (p<0.001),而性酸酶在肝硬化患者中没有相关 (p=0.100).
- 鹿特丹标准在肝硬化患者的5年终点事件中显示出最高的预测准确性 (AUC=0.652),并确定了预后较差的患者.
结论:
- 组织学分类将非肝硬化与肝硬化区分开来,在PBC的早期与高级阶段分层上提供了优越的临床实用性.
- 鹿特丹标准在临床上适用于评估组织性肝硬化患者的生物化学反应.
相关概念视频
Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...

